Dose and schedule effects of cisplatin on the related acute iron changes

C. F. Pollera, F. Ameglio, M. Nardi, P. Marolla, P. Carlini, A. M. Frasca

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

To investigate the relationships between cisplatin and the related erythropoiesis impairment, 14 patients receiving very-high-dose cisplatin (40 mg/m2/day for 5 days) and 17 patients receiving standard-high-dose cisplatin (either a single dose of 100 or 20 mg/m2/day for 5 days) entered this study. Iron, ferritin, hemoglobin, and reticulocyte levels were evaluated before, 4 and 6 days after each course of cisplatin. A complete blood count was obtained weekly. During the 1st week after chemotherapy, iron and ferritin levels significantly increased, and the reticulocyte count decreased. Iron changes depend on the cisplatin dose, but are not related to the different schedules employed. The severity of subacute anemia was found to be dependent on the cisplatin dose administered and on hemoglobin pretreatment levels. Some relationships between cisplatin, iron changes, and the subacute hemoglobin decrease are described.

Original languageEnglish
Pages (from-to)133-138
Number of pages6
JournalOncology
Volume47
Issue number2
Publication statusPublished - 1990

Fingerprint

Cisplatin
Appointments and Schedules
Iron
Hemoglobins
Ferritins
Reticulocyte Count
Blood Cell Count
Erythropoiesis
Reticulocytes
Anemia
Drug Therapy

Keywords

  • anemia
  • cisplatin
  • iron

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Pollera, C. F., Ameglio, F., Nardi, M., Marolla, P., Carlini, P., & Frasca, A. M. (1990). Dose and schedule effects of cisplatin on the related acute iron changes. Oncology, 47(2), 133-138.

Dose and schedule effects of cisplatin on the related acute iron changes. / Pollera, C. F.; Ameglio, F.; Nardi, M.; Marolla, P.; Carlini, P.; Frasca, A. M.

In: Oncology, Vol. 47, No. 2, 1990, p. 133-138.

Research output: Contribution to journalArticle

Pollera, CF, Ameglio, F, Nardi, M, Marolla, P, Carlini, P & Frasca, AM 1990, 'Dose and schedule effects of cisplatin on the related acute iron changes', Oncology, vol. 47, no. 2, pp. 133-138.
Pollera CF, Ameglio F, Nardi M, Marolla P, Carlini P, Frasca AM. Dose and schedule effects of cisplatin on the related acute iron changes. Oncology. 1990;47(2):133-138.
Pollera, C. F. ; Ameglio, F. ; Nardi, M. ; Marolla, P. ; Carlini, P. ; Frasca, A. M. / Dose and schedule effects of cisplatin on the related acute iron changes. In: Oncology. 1990 ; Vol. 47, No. 2. pp. 133-138.
@article{8621e1bf69654789be48228f69b19b4f,
title = "Dose and schedule effects of cisplatin on the related acute iron changes",
abstract = "To investigate the relationships between cisplatin and the related erythropoiesis impairment, 14 patients receiving very-high-dose cisplatin (40 mg/m2/day for 5 days) and 17 patients receiving standard-high-dose cisplatin (either a single dose of 100 or 20 mg/m2/day for 5 days) entered this study. Iron, ferritin, hemoglobin, and reticulocyte levels were evaluated before, 4 and 6 days after each course of cisplatin. A complete blood count was obtained weekly. During the 1st week after chemotherapy, iron and ferritin levels significantly increased, and the reticulocyte count decreased. Iron changes depend on the cisplatin dose, but are not related to the different schedules employed. The severity of subacute anemia was found to be dependent on the cisplatin dose administered and on hemoglobin pretreatment levels. Some relationships between cisplatin, iron changes, and the subacute hemoglobin decrease are described.",
keywords = "anemia, cisplatin, iron",
author = "Pollera, {C. F.} and F. Ameglio and M. Nardi and P. Marolla and P. Carlini and Frasca, {A. M.}",
year = "1990",
language = "English",
volume = "47",
pages = "133--138",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "2",

}

TY - JOUR

T1 - Dose and schedule effects of cisplatin on the related acute iron changes

AU - Pollera, C. F.

AU - Ameglio, F.

AU - Nardi, M.

AU - Marolla, P.

AU - Carlini, P.

AU - Frasca, A. M.

PY - 1990

Y1 - 1990

N2 - To investigate the relationships between cisplatin and the related erythropoiesis impairment, 14 patients receiving very-high-dose cisplatin (40 mg/m2/day for 5 days) and 17 patients receiving standard-high-dose cisplatin (either a single dose of 100 or 20 mg/m2/day for 5 days) entered this study. Iron, ferritin, hemoglobin, and reticulocyte levels were evaluated before, 4 and 6 days after each course of cisplatin. A complete blood count was obtained weekly. During the 1st week after chemotherapy, iron and ferritin levels significantly increased, and the reticulocyte count decreased. Iron changes depend on the cisplatin dose, but are not related to the different schedules employed. The severity of subacute anemia was found to be dependent on the cisplatin dose administered and on hemoglobin pretreatment levels. Some relationships between cisplatin, iron changes, and the subacute hemoglobin decrease are described.

AB - To investigate the relationships between cisplatin and the related erythropoiesis impairment, 14 patients receiving very-high-dose cisplatin (40 mg/m2/day for 5 days) and 17 patients receiving standard-high-dose cisplatin (either a single dose of 100 or 20 mg/m2/day for 5 days) entered this study. Iron, ferritin, hemoglobin, and reticulocyte levels were evaluated before, 4 and 6 days after each course of cisplatin. A complete blood count was obtained weekly. During the 1st week after chemotherapy, iron and ferritin levels significantly increased, and the reticulocyte count decreased. Iron changes depend on the cisplatin dose, but are not related to the different schedules employed. The severity of subacute anemia was found to be dependent on the cisplatin dose administered and on hemoglobin pretreatment levels. Some relationships between cisplatin, iron changes, and the subacute hemoglobin decrease are described.

KW - anemia

KW - cisplatin

KW - iron

UR - http://www.scopus.com/inward/record.url?scp=0025019947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025019947&partnerID=8YFLogxK

M3 - Article

C2 - 2314826

AN - SCOPUS:0025019947

VL - 47

SP - 133

EP - 138

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 2

ER -